Sort   by:  
 Page size 
UnknownRituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.
Not available
S-EPMC4876343 | biostudies-literature
UnknownThe addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
Not available
S-EPMC4938327 | biostudies-literature
UnknownAnchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria.
Not available
S-EPMC12224562 | biostudies-literature
UnknownPrognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Not available
S-EPMC6620111 | biostudies-literature
UnknownPharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies.
Not available
S-EPMC7687070 | biostudies-literature
UnknownEvaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Not available
S-EPMC6120509 | biostudies-literature
UnknownAcalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Not available
S-EPMC8547923 | biostudies-literature
UnknownThe phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Not available
S-EPMC6284216 | biostudies-literature
UnknownUse of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
Not available
S-EPMC6084297 | biostudies-literature
UnknownImprovement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Not available
S-EPMC6527106 | biostudies-literature
Sort   by:  
 Page size